Caseware UK (AP4) 2023.0.135 2023.0.135 2024-03-312024-03-31true32023-04-01property2falsetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 8293360 2023-03-31 8293360 2022-04-01 2023-03-31 8293360 c:CurrentFinancialInstruments c:WithinOneYear 2023-03-31 8293360 c:CurrentFinancialInstruments c:WithinOneYear 2024-03-31 8293360 2024-03-31 8293360 6 2023-04-01 2024-03-31 8293360 2023-04-01 2024-03-31 8293360 c:ShareCapital 2023-03-31 8293360 c:ShareCapital 2024-03-31 8293360 c:RetainedEarningsAccumulatedLosses 2023-03-31 8293360 c:RetainedEarningsAccumulatedLosses 2024-03-31 8293360 d:PrivateLimitedCompanyLtd 2023-04-01 2024-03-31 8293360 d:FullAccounts 2023-04-01 2024-03-31 8293360 d:FRS102 2023-04-01 2024-03-31 8293360 d:Director2 2023-04-01 2024-03-31 8293360 c:CurrentFinancialInstruments 2023-03-31 8293360 c:CurrentFinancialInstruments 2024-03-31 8293360 d:AuditExempt-NoAccountantsReport 2023-04-01 2024-03-31 iso4217:GBP xbrli:pure

Registered number: 8293360










DINNINGTON GP PHARMA LIMITED








UNAUDITED

FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2024

 
DINNINGTON GP PHARMA LIMITED
REGISTERED NUMBER: 8293360

BALANCE SHEET
AS AT 31 MARCH 2024

2024
2023
Note
£
£

Fixed assets
  

Investments
 4 
60
60

  
60
60

Current assets
  

Debtors: amounts falling due within one year
 5 
1,210
1,210

Cash at bank and in hand
  
3,482
2,123

  
4,692
3,333

Creditors: amounts falling due within one year
 6 
(2,155)
(973)

Net current assets
  
 
 
2,537
 
 
2,360

Total assets less current liabilities
  
2,597
2,420

  

Net assets
  
2,597
2,420


Capital and reserves
  

Called up share capital 
  
1,210
1,210

Profit and loss account
  
1,387
1,210

  
2,597
2,420


Page 1

 
DINNINGTON GP PHARMA LIMITED
REGISTERED NUMBER: 8293360
    
BALANCE SHEET (CONTINUED)
AS AT 31 MARCH 2024

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 18 July 2024.



Dr Lorna Kay McKenna
Director

The notes on pages 3 to 4 form part of these financial statements.

Page 2

 
DINNINGTON GP PHARMA LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

1.


General information

Dinnington GP Pharma Limited is a private company limited by shares, incorporated in England and Wales (registered number: 08293360). The registered office is Anston Medical Centre, Quarry Lane, North Anston, Sheffield, S25 4DB.  The principal activity of the Company continued to be a holding company of Dinnington Partnership Limited.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The following principal accounting policies have been applied:

 
2.2

Going concern

The company continues to adopt the going concern basis in preparing its financial statements.

 
2.3

Valuation of investments

Investments in unlisted Company shares, whose market value can be reliably determined, are remeasured to market value at each balance sheet date. Gains and losses on remeasurement are recognised in the Statement of Income and Retained Earnings for the period. Where market value cannot be reliably determined, such investments are stated at historic cost less impairment.

 
2.4

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.5

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.6

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.

Page 3

 
DINNINGTON GP PHARMA LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

3.


Employees

The average monthly number of employees, including directors, during the year was 2 (2023 - 3).


4.


Fixed asset investments





Unlisted investments

£



Cost or valuation


At 1 April 2023
60



At 31 March 2024
60





5.


Debtors

2024
2023
£
£


Called up share capital not paid
1,210
1,210



6.


Creditors: Amounts falling due within one year

2024
2023
£
£

Trade creditors
1,182
-

Other creditors
373
373

Accruals and deferred income
600
600

2,155
973


Page 4